| Authors: |
Kirtley P; Oregon Health and Science University, Vaccine and Gene Therapy Institute, Beaverton, OR, USA., Martinson T; Oregon Health and Science University, Vaccine and Gene Therapy Institute, Beaverton, OR, USA., Donnellan FR; Department of Paediatrics and Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK., Aleshnick M; Oregon Health and Science University, Vaccine and Gene Therapy Institute, Beaverton, OR, USA., Nielsen K; Oregon Health and Science University, Vaccine and Gene Therapy Institute, Beaverton, OR, USA., Mayer BT; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Borate B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Huang TJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Pipini D; Department of Paediatrics and Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK., Rigby CA; Department of Paediatrics and Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK., Quinkert D; Department of Paediatrics and Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK., Silk SE; Department of Paediatrics and Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK., Minassian AM; Department of Paediatrics and Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK., McHugh K; Department of Paediatrics and Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK., Draper SJ; Department of Paediatrics and Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK., Wilder BK; Oregon Health and Science University, Vaccine and Gene Therapy Institute, Beaverton, OR, USA. Electronic address: wilderb@ohsu.edu. |
